Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- cell therapy
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279375
IPSCIO Record ID: 263905
This agreement includes non-exclusive grants back from Licensee to Licensor.
IPSCIO Record ID: 256328
IPSCIO Record ID: 301043
IPSCIO Record ID: 324645
8,114,407 – EphA2 T-cell epitopes and uses therefor
Proprietary Vaccine shall mean a vaccine which is developed or being developed for a therapeutic indication based on biological activity that is solely-owned or in-licensed by Licensee from third parties and which is not covered by the Patent Rights and which is not Licensed Product hereunder. For the avoidance of doubt, the Il-13 Alpha2 Peptide Analogues licensed under the Exclusive Patent License Agreement shall constitute a Proprietary Vaccine.
IPSCIO Record ID: 237265
Licensor grants a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import nucleic acid sequences encoding for such Additional Antigen in the Field, and to make, have made, use, sell, offer to sell and import Licensee Product(s) containing a nucleic acid sequence encoding for such Additional Antigen in the Field.
For the Licensors Applicator and/or Licensors Custom Components, Licensor grants an exclusive, sublicenseable license under the Licensors Patent Rights and Device Custom Know-How to use, sell, offer to sell and import Licensors Applicators and Licensors Custom Components solely for use with a Licensee Product in the Field.
For the Trademark License, Licensor grants a non-exclusive, sublicensable license in the Field in the Territory to use such trademarks and/or trade names Controlled by Licensor, to the extent that such trademarks and/or trade names relate to Licensors Technology, solely in connection with the use, sale, offer to sell and/or import of Licensee Product.
A single Indication shall include the primary disease and variants or sub-divisions or sub-classifications within such primary disease. For example, for purposes of the Agreement, breast cancer is a single Indication; treatment of and first line treatment of refractory metastatic breast cancer shall be treated as sub-classifications within the single Indication of breast cancer. Treatment and prophylaxis of the same disease (e.g. breast cancer) shall be treated as the same Indication.
IPSCIO Record ID: 257492
With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.
As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.
Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.
Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.
Treatment vaccines means a bulk or finished vaccine.
IPSCIO Record ID: 364010
Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use. At Licenseeâ€™s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.
Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.
Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line â€œAD100-gp96/III.Aâ€.
Patent Rights shall mean the following United States Patent applications U.S. provisional patent application serial number 60/075.358 entitled â€œModified Heat Shock Protein-antigenic Peptide Complexâ€ and filed on February 20, 1998 U.S. patent application serial number 09 253.439 entitled â€œModified Heat Shock Protein-Antigenic Peptide Complexâ€ and filed on February 19, 1999 U.S. patent application serial number 11/878.460 entitled â€œRecombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complexâ€ and filed on July 24, 2008 all United States patents and foreign patents and patent applications based on these U.S. applications all divisionals, continuations of the foregoing and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358. U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112Â¶1; and any re-examinations or reissues of the foregoing. â€œPatent Rightsâ€ shall not include Excluded Patent Rights.
Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.